E-HEALTH - E-SANTE - PHARMAGEEK
287.1K views | +35 today
Follow

Major grant for development of ehealth program for cardiac rehabilitation  #hcsmeufr #esante #digitalhealth

From www.radboudumc.nl

Every year, more than 3 million people in Europe experience a heart attack. For half of them, this is not the first time. Most of these recurrent heart attacks can be prevented by improving the lifestyle after the first heart attack, for which patients are often offered cardiac rehabilitation. These programs consist of exercise and lifestyle recommendations. Cardiac rehabilitation is provided at specialized centers.
 
According to estimates, if all cardiac patients were to undergo cardiac rehabilitation, the mortality from myocardial infarctions could fall by 26 percent and hospital admissions by more than 30 percent. Despite these benefits, less than half of cardiac patients receive cardiac rehabilitation. This lack of participation is mainly due the distance to the cardiac rehabilitation centers, which patients experience as being too far. There are also many objections to the limited possibilities for taking an individualized program.
 
Research has shown that an internet-based rehabilitation program can achieve the same results as rehabilitation at a center. An e-health application for cardiac rehabilitation could therefore eliminate many obstacles for patients.

 

However, such an application is not yet available.

 

With Eurostar funding of € 1.9 million, a European consortium of researchers and companies will create CaRe, a mobile platform for cardiac rehabilitation.

 

Maria Hopman is creating this e-health program for cardiac rehabilitation together with a consortium of Danish and Swiss companies. Starting in 2021, the program will be available for physiotherapists and hospitals in Europe.

 

more at https://www.radboudumc.nl/en/news/2018/major-grant-for-development-of-e-health-program-for-cardiac-rehabilitation

 

 

 

 

nrip's curator insight, October 20, 2018 1:37 AM

This week I am finding a lot of exciting pilots being funded well enough to take them to commercialization. Which is excellent. However, I find a number of such pilots seem to overlap in ideas and purpose. I wish there is collaboration of ideas between similar projects, especially, if not only to avoid another lack of interoperability scenario, arising 3-4 years from now, and causing pain for patients and care givers alike.

Estonia and Finland will start exchanging digital prescriptions at the end of 2018  #hcsmeufr #esante

From www.euractiv.com

Estonia and Finland will start exchanging digital prescriptions at the end of the year, in a groundbreaking move that Estonian Health Minister Riina Sikkut said she hoped other EU countries will follow.

 

Speaking to EURACTIV.com on the sidelines of the European Health Forum in Gastein, Austria, Sikkut said that in Estonia, it is common practice for healthcare professionals to use the e-health system to exchange patient medical records.

 

“But it is also important for people who have a need for healthcare services abroad to have his or her health data available to a doctor, nurse or a pharmacist so that they could also provide quality healthcare services and continuity of care,” she said.

 

The cross-border flow of data has taken centre stage in the discussion in Brussels. Right now, when citizens move to another EU member state, their healthcare data is in fact simply “lost”.

 

Advocates of the digitisation of healthcare say data mobility, or the “5th freedom”, in the EU could unlock the potential of innovation in the sector and make EU patients’ lives easier.

 

Estonia is known for its digitisation push in all sectors, and during its EU Presidency (July-December 2017), it took significant steps to create a “coalition of the willing” of EU member states to speed up healthcare data mobility in Europe.

 
 
No comment yet.

Digital health is going to need medical approval and a great UI

From gigaom.com

So far the internet of things hasn’t made much headway into patient care in the medical setting, but consumers are buying wellness devices for a variety of reasons. Will the medical world embrace that data?

 

The intersection of healthcare and connected devices was thrown into high relief these last few weeks as both Apple and Samsung unveiled ecosystems to take consumer health data and turn it into actionable intelligence.

 

But this week’s guests at the Weekly podacst at GigaOm are confident that as advanced as consumer-grade consumer grade health devices get, they won’t become something doctors are hot on for years to come — if ever.

 

In this week’s podcast Stacey Higginbotham discusses medical connected devices and where it may meet the consumer with Rick Valencia from Qualcomm Life. Will doctor’s prescribe our apps or devices? 


 Listen to the podcast at  http://soundcloud.com/gigaom-internet-of-things  Original article at http://gigaom.com/2014/06/09/digital-health-is-going-to-need-medical-approval-and-a-great-ui/ ;

Vigisys's curator insight, June 15, 2014 4:22 AM

Un podcast intéressant qui évoque les freins à l'utilisation médicale des objets connectés. On y évoque le besoin de valider les usages avec des études cliniques et d'adapter les interfaces à un usage professionnel. Que du bon sens !

Trends and Drivers of Primary Care Physicians' Use of #HealthIT

From www.commonwealthfund.org

Commonwealth Fund researchers analyzed data from surveys of primary care physicians conducted in 2009 and 2012 to check on the progress of health IT adoption.



Adoption of health information technology (HIT) by physician practices rose considerably from 2009 to 2012, yet solo physicians lag practices of 20 or more and certain functions—like electronically exchanging information with other physicians—have been adopted by only a minority of providers. Physicians who are part of an integrated delivery system, share resources with other practices, and are eligible for financial incentives, have higher rates of HIT adoption.


Doctors are using HIT in greater numbers, spurred on in part by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, which provided billions to help build a national HIT infrastructure. Commonwealth Fund researchers analyzed data from surveys of primary care physicians conducted in 2009 and 2012 to check on the progress of HIT adoption and to see how certain factors—like being part of an integrated health system or using shared technical assistance programs—can influence technology take-up.

Key Findings
  • From 2009 to 2012, the rate of adoption of electronic medical records (EMRs) by U.S. primary care physicians increased by half, from 46 percent to 69 percent. HIT use rose particularly in order entry management: the proportion of physicians able to send prescriptions electronically to pharmacies nearly doubled, from 34 percent to 66 percent; electronic prescribing increased from 40 percent to 64 percent; and electronic ordering of lab tests grew from 38 percent to 54 percent.
  • In 2012, 33 percent of primary care physicians could exchange clinical summaries with other doctors, and 35 percent could share lab or diagnostic tests with doctors outside their practice.
  • As of 2012, a minority of physicians provided electronic access for patients. Roughly one-third or fewer allowed patients to electronically view test results, make appointments, or request prescription refills.
  • Practice size is a major determinant of HIT adoption. Half of physicians in solo practices use EMRs, compared with 90 percent of those in practices of 20 or more physicians.
  • Physicians who are part of an integrated delivery system (like Kaiser Permanente or the Veterans Administration), those who have arrangements with other practices to share resources (technical assistance programs for clinical information systems or quality improvement), and those who are eligible for financial incentives, have higher rates of HIT adoption.

more at http://www.commonwealthfund.org/Publications/In-the-Literature/2014/Jan/Where-Are-We-on-the-Diffusion-Curve.aspx


No comment yet.

Top health industry issues of 2014 #musterad #hcsmeufr #hcsmeu #hcsm

From www.pwc.com

Implications of integrating technology:


Under increasing pressure to keep costs down, providers should promote technologies that help manage patients’ health outside of costly care settings.


Shouldering more of their medical costs, health-conscious consumers may be more willing to pay for mobile and other technologies to help manage their health.


Drug and device companies must understand consumer behavior and satisfaction in the social media era.


Reimbursing non-traditional, mobile-enabled therapies may allow insurers to reduce medical costs.

No comment yet.

FDA Helping to Advance Treatments Tailored to Patients

From www.fda.gov

Personalized medicine is the tailoring of a medical treatment to the individual characteristics, needs and preferences of a patient. Many recent advances involve using a patient's genetic information to guide his or her treatment.


Developing a truly personalized approach to patient care will require fundamental advances in the understanding of the biological, anatomical and physiological mechanisms that underlie disease, and how they are affected by environmental, genetic, social and cultural factors.


To describe its unique responsibilities and its efforts in facilitating the advancement of personalized medicine, the Food and Drug Administration (FDA) has released a new report entitled "Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development 


FDA's commitment to personalized medicine dovetails with its focus on advancing regulatory science, which is the science of developing new tools, standards and approaches to assess the safety, effectiveness, quality and performance of FDA-regulated products.


Here are some examples from the report of how FDA is using regulatory science to help speed the development of promising new personalized medicine therapies.


Virtual patient: Advances in medical imaging and the power of computers to create virtual, anatomically correct models of the human body have enabled the use of patient-specific computer simulations in clinical practice and medical device development. This has facilitated the creation of personalized, custom-built medical devices. FDA's Center for Devices and Radiological Health (CDRH) is developing a publicly available digital library of such models and simulations. This space for collaboration and sharing will help advance the personalization of medical device development and use.


Clinical Trial Designs and Methods: FDA is working to refine clinical trial design and statistical methods of analysis to address issues that often arise in the development of targeted therapeutics. The agency is also looking specifically at clinical trials for the development of cancer drugs. For example, FDA is participating in the "I-SPY 2 Trial," a groundbreaking clinical trial model that will help scientists quickly test the most promising drugs in development for women with rapidly growing breast cancers.


Biology of cancer: FDA's National Center for Toxicological Research (NCTR) conducts research to improve the understanding of cancer's underlying biology. A research project focused on the KRAS oncogene, for example, established that many tumors carry subpopulations of KRAS mutant cells, which can contribute to an acquired resistance to some cancer treatments.


Identification of genetic risk factors for vaccine reactions: FDA's Center for Biologics Evaluation and Research is involved in research collaborations that focus on identifying genetic risk factors associated with negative reactions to vaccines.


Genetics and cardiovascular risk: In collaboration with researchers at the University of Maryland, scientists at NCTR are conducting research to identify genetic factors that interact with common lifestyle factors—such as diet and drug exposure—to contribute to cardiovascular disease.


Personalized medicine for heart devices: Researchers at CDRH have made major advances in understanding the underlying biology of heart disease. They have used new methods to analyze electrocardiograms to identify the causes of heart disease and to predict which patients will benefit from specific cardiovascular treatments. These new methods are being used by outside research groups and may be used to design more efficient clinical trials in the future.


Joel Finkle's curator insight, November 25, 2014 10:33 AM

New FDA report on personalized medicine.  We're not quite to the home "autodoc" but more treatments will be tailored to each patient's genome, for greater safety, efficacy, and probably cost.